GlassScriptPhysician profile
Ericka T Flood
NPI 1346419462
$10,726.25
in general payments reported to CMS, 2019-2025
59 companies · $233 in 2025
The $233 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,272 · 2020: $2,886 · 2021: $2,273 · 2022: $2,742 · 2023: $202 · 2024: $119 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $553.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,097.30 | 2019-2025 | Wegovy |
| Abbvie INC. | $952.30 | 2019-2022 | |
| Bausch Health US, LLC | $804.49 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $489.08 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $487.82 | 2019-2023 | Cycloset |
| Amarin Pharma, INC. | $478.97 | 2019-2022 | |
| Aytu Biopharma, INC. | $451.84 | 2020 | |
| Tandem Diabetes Care, INC. | $400.00 | 2020 | |
| Amgen INC. | $362.33 | 2019-2025 | |
| Lilly USA, LLC | $289.40 | 2019-2022 | |
| Ibsa Pharma INC. | $289.35 | 2019-2022 | |
| Abbott Laboratories | $272.19 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $267.11 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $252.19 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $227.39 | 2019-2022 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ericka Flood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.